Skye Bioscience Inc (OTCQB:SKYE) CEO Punit Dhillon joined Proactive with updates on the company's Phase 1 and 2 trials for its SBI-100 Ophthalmic Emulsion.
Dhillon told Proactive that Skye plans to file its Investigational New Drug (IND) for a US phase 2 clinical study in the fourth quarter of this year.
Meanwhile, the completion of the Phase 1 drug has been updated to early September 2022. The company also recently received regulatory approval for its first in-human Phase 1 clinical study of SBI-100.
"Phase 1 ... we are going to continue to generate the data and push towards getting safety and tolerability data in that healthy volunteer study," Dhillon said. "What's really exciting for us is moving our Phase 2 program aggressively forward, which is where we're, again, measuring safety but also looking at efficacy in glaucoma patients and patients that have ocular hypertension."